Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Defending Core Fundamentals Despite Setback From Lovaza Litigation
Tweet Send to a Friend
Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (NYSE: PRX) price target of $48.00.
Analyst, Elliot Wilbur ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Elliot Wilbur ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
